Does neoadjuvant chemotherapy improve survival in patients with resectable thoracic oesophageal cancer?
-
Report By: Shahzad G. Raja, Kareem Salhiyyah, and Kumaresan Nagarajan - Specialist Registrars in Cardiothoracic Surgery
-
Search checked by Joel Dunning - Specialist Registrar in Cardiothoracic Surgery RCS
-
Institution: Western Infirmary Glasgow and Royal Hospital for Sick Children, Glasgow
-
Date Submitted: 28th November 2007
-
Date Completed: 14th February 2008
-
Last Modified: 28th November 2007
-
Status:
Green (complete)
Three Part Question
In [patients with resectable oesophageal carcinoma] does [neoadjuvant chemotherapy compared to surgery alone] improve [survival]?Clinical Scenario
You are attending the thoracic multidisciplinary meeting. The case of a 44-year-old man with localised, resectable oesophageal carcinoma is discussed. One of the oncologists suggests neoadjuvant chemotherapy for this patient, however, the thoracic surgeon disagrees with his suggestion claiming that there is no benefit of this strategy and it would make surgery more difficult. You resolve to investigate this further.
Search Strategy
